Starling Oncology/$STLN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Starling Oncology
Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
- Ticker
- $STLN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 641
- Headquarters
- Cerritos, United States
- Website
- starlingoncology.com
STLN Metrics
BasicAdvanced
$428M
-
-$0.29
0.41
-
Price and volume
Market cap
$428M
Beta
0.41
52-week high
$7.13
52-week low
$2.32
Average daily volume
2.5M
Financial strength
Current ratio
1.113
Quick ratio
0.79
Long term debt to equity
-2.422
Total debt to equity
-2.751
Interest coverage (TTM)
-2.02%
Profitability
EBITDA (TTM)
-14.41
Gross margin (TTM)
16.75%
Net profit margin (TTM)
-5.73%
Operating margin (TTM)
-3.39%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
-7.48%
Return on equity (TTM)
143.21%
Valuation
Price to revenue (TTM)
0.696
Price to book
-11.47
Price to tangible book (TTM)
-8.01
Price to free cash flow (TTM)
22.929
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
0.183
Growth
Revenue change (TTM)
34.58%
Earnings per share change (TTM)
-53.89%
3-year revenue growth (CAGR)
26.04%
3-year earnings per share growth (CAGR)
-31.38%
What the Analysts think about STLN
Analyst ratings (Buy, Hold, Sell) for Starling Oncology stock.
Analyst projections of the future price of Starling Oncology stock.
Bulls say / Bears say
Third-quarter revenue rose 24% year on year, while adjusted EBITDA reached $3.4 million for a second consecutive positive quarter. Specialty pharmacy revenue grew 44%, with a 24% gross margin, adding momentum to the core growth engine. (GlobeNewswire)
The delegated-care model is expanding beyond Florida: Starling launched a statewide Oregon contract covering about 40,000 Medicare Advantage lives and expects capitated revenue to double in 2027. Its identified contract pipeline also points to room for further expansion, although not every opportunity will convert. (StockAnalysis)
Cash generation has improved sharply: free cash flow was $20.2 million for the first nine months of 2026, compared with a $26.9 million outflow a year earlier. That provides a stronger funding base as the company grows. (SEC)
Capitation margins remain exposed to medical-cost swings: the medical loss ratio was 81% in Q3, up from 67.8% a year earlier, and management expects 85%–90% in 2027 as new lives are added. A higher ratio leaves less premium revenue to cover overhead and profit. (StockAnalysis)
The business still reported a $15.7 million GAAP net loss in Q3 despite positive adjusted EBITDA. It also had $72.5 million of long-term debt and $5 million drawn on its revolving facility, leaving limited room for a setback before sustained profitability is established. (SEC)
Contract growth has ramped more slowly than previously expected: Starling cut its 2026 capitated-revenue outlook from $150 million to about $110 million, and said its anchor health-plan partners would not immediately expand statewide. Delays could weigh on the growth plan if new contracts take longer to scale. (StockAnalysis, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
STLN Financial Performance
Revenues and expenses
STLN Earnings Performance
Company profitability
Upcoming events
No upcoming events
STLN News
AllArticlesVideos
Funds containing STLN
Fund name | Fund size | $STLN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.